Bupropion

CHEMBL894 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
21 hours
Bioavailability
Protein Binding
Molecular Weight
239.7 g/mol
LogP
3.2
Phase
4

Distinct among antidepressants for not typically causing sexual dysfunction or weight gain, bupropion inhibits the reuptake of norepinephrine and dopamine rather than serotonin. It treats major depressive disorder and seasonal affective disorder and, under separate branding, aids smoking cessation. Sold as Wellbutrin, Aplenzin, and Zyban, it has the formula C13H18ClNO. Because it lowers the seizure threshold in a dose-dependent way, its use is limited in patients with seizure risk. This monocyclic aminoketone remains one of the more commonly prescribed non-serotonergic antidepressants.

An antidepressant and smoking cessation aid that inhibits the reuptake of norepinephrine and dopamine in the brain. It is used to treat major depressive disorder, seasonal affective disorder, and to help people quit smoking. Unlike many antidepressants, it does not typically cause sexual dysfunction or weight gain, and is associated with a dose-dependent risk of seizures.

น้ำหนักโมเลกุล

239.7420 g/mol

LogP

3.20

TPSA

29.10 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

หมวดหมู่ยา

Pharmacokinetics (PK)

Half-Life 21 hours

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1

InChI

InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3

Molecular Formula

C13H18ClNO

HBD / HBA

1 / 2

พันธะที่หมุนได้

4

อะตอมหนัก

16

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An antidepressant and smoking cessation aid that inhibits the reuptake of norepinephrine and dopamine in the brain. It is used to treat major depressive disorder, seasonal affective disorder, and to help people quit smoking. Unlike many antidepressants, it does not typically cause sexual dysfunction or weight gain, and is associated with a dose-dependent risk of seizures.

Key pharmacokinetic parameters for Bupropion: Half-life: 21 hours.

Yes, Bupropion is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL894. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 444. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.